Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein
2022
Elisabetta Marini | Marco Marino | Giulia Gionfriddo | Federica Maione | Marta Pandini | Daniele Oddo | Marta Giorgis | Barbara Rolando | Federica Blua | Simone Gastaldi | Serena Marchiò | Sandra Kovachka | Francesca Spyrakis | Eleonora Gianquinto | Federica Di Nicolantonio | Massimo Bertinaria
BRAF is a serine/threonine kinase frequently mutated in human cancers. BRAFV600E mutated protein is targeted through the use of kinase inhibitors which are approved for the treatment of melanoma: however, their long-term efficacy is hampered by resistance mechanisms. The PROTAC-induced degradation of BRAFV600E has been proposed as an alternative strategy to avoid the onset of resistance. In this study, we designed a series of compounds where the BRAF kinase inhibitor encorafenib was conjugated to pomalidomide through different linkers. The synthesized compounds maintained their ability to inhibit the kinase activity of mutated BRAF with IC50 values in the 40&ndash:88 nM range. Selected compounds inhibited BRAFV600E signaling and cellular proliferation of A375 and Colo205 tumor cell lines. Compounds 10 and 11, the most active of the series, were not able to induce degradation of mutated BRAF. Docking and molecular dynamic studies, conducted in comparison with the efficient BRAF degrader P5B, suggest that a different orientation of the linker bearing the pomalidomide substructure, together with a decreased mobility of the solvent-exposed part of the conjugates, could explain this behavior.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by Multidisciplinary Digital Publishing Institute
